Guardant Health Shield

Guardant Health has launched Shield, the company's first blood-based test for the detection of early-stage colorectal cancer. The test is performed on a simple blood draw sample and is intended for adults age 45 and older who are not up to date with recommended screening guidelines, show no symptoms, and are at average risk for CRC. In a 300-patient validation, the test showed 91 percent sensitivity, including 90 percent sensitivity for Stage I, 97 percent for Stage II, and 86 percent for Stage III cancers, and 20 percent sensitivity for advanced adenomas, with 92 percent specificity.